Business Description
Seres Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US81750R1023
Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.71 | |||||
| Equity-to-Asset | 0.13 | |||||
| Debt-to-Equity | 3.91 | |||||
| Debt-to-EBITDA | -1.63 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -7.32 | |||||
| Beneish M-Score | 0.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 33.4 | |||||
| 3-Year EBITDA Growth Rate | 9.6 | |||||
| 3-Year EPS without NRI Growth Rate | 7.4 | |||||
| 3-Year FCF Growth Rate | 6.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.81 | |||||
| 9-Day RSI | 58.93 | |||||
| 14-Day RSI | 57.21 | |||||
| 6-1 Month Momentum % | 11.95 | |||||
| 12-1 Month Momentum % | -25.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 1.12 | |||||
| Cash Ratio | 1.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.9 | |||||
| Shareholder Yield % | -14.76 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -39.59 | |||||
| Net Margin % | -20.17 | |||||
| FCF Margin % | -125.41 | |||||
| ROA % | -8.12 | |||||
| ROIC % | -28.88 | |||||
| ROC (Joel Greenblatt) % | -49.32 | |||||
| ROCE % | -28.4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.99 | |||||
| PB Ratio | 6.81 | |||||
| Price-to-Tangible-Book | 6.69 | |||||
| EV-to-EBIT | -3.02 | |||||
| EV-to-EBITDA | -3.33 | |||||
| EV-to-Revenue | 1.52 | |||||
| EV-to-Forward-Revenue | 2.61 | |||||
| EV-to-FCF | -1.21 | |||||
| Earnings Yield (Greenblatt) % | -33.11 | |||||
| FCF Yield % | -96.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Seres Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 115.84 | ||
| EPS (TTM) (€) | -0.222 | ||
| Beta | 1.44 | ||
| Volatility % | 101.99 | ||
| 14-Day RSI | 57.21 | ||
| 14-Day ATR (€) | 0.044831 | ||
| 20-Day SMA (€) | 0.82926 | ||
| 12-1 Month Momentum % | -25.43 | ||
| 52-Week Range (€) | 0.5194 - 1.47 | ||
| Shares Outstanding (Mil) | 170.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Seres Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Seres Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Seres Therapeutics Inc Frequently Asked Questions
What is Seres Therapeutics Inc(FRA:1S9)'s stock price today?
The current price of FRA:1S9 is €0.87. The 52 week high of FRA:1S9 is €1.47 and 52 week low is €0.52.
When is next earnings date of Seres Therapeutics Inc(FRA:1S9)?
The next earnings date of Seres Therapeutics Inc(FRA:1S9) is 2025-03-05 Est..
Does Seres Therapeutics Inc(FRA:1S9) pay dividends? If so, how much?
Seres Therapeutics Inc(FRA:1S9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers